ACETO Reports Fiscal 2014 Fourth Quarter and Year End Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Aceto Corp (ACET) Tops Q3 EPS by 4c
September 4, 2014 5:01 PM EDTAceto Corp (NASDAQ: ACET) reported Q3 EPS of $0.21, $0.04 better than the analyst estimate of $0.17. Revenue for the quarter came in at $139.6 million versus the consensus estimate of $134.23 million.
"ACETO made significant progress during fiscal 2014 toward our long-term strategy of becoming a more human health-oriented company. An expanded and enhanced management team at our generic drug division, Rising Pharmaceuticals, the acquisition of the generic pharmaceutical company, PACK Pharmaceuticals, including its robust product pipeline, new finished dose product launches and a near doubling of research and development spend versus fiscal 2013 all contributed to this progress.... More
